Phathom Pharmaceuticals, Inc. Accounts Payable

Accounts Payable of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Accounts Payable growth rates and interactive chart. Accounts payable (AP) represents a company's obligation to pay off a short-term debt to its creditors or suppliers. Accounts payable are amounts due to vendors or suppliers for goods or services received that have not yet been paid for. The sum of all outstanding amounts owed to vendors is shown as the accounts payable balance on the company's balance sheet. The increase or decrease in total AP from the prior period appears on the cash flow statement.

Highlights and Quick Summary

  • Accounts Payable for the quarter ending June 29, 2021 was $5.4 Million (a -50.25% decrease compared to previous quarter)
  • Year-over-year quarterly Accounts Payable increased by 12.8%
  • Annual Accounts Payable for 2020 was $16.8 Million (a 2300.86% increase from previous year)
  • Annual Accounts Payable for 2019 was $699 Thousand (a 1170.91% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Accounts Payable of Phathom Pharmaceuticals, Inc.

Most recent Accounts Payableof PHAT including historical data for past 10 years.

Interactive Chart of Accounts Payable of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Accounts Payable for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $5.4 $10.86
2020 $16.78 $4.79 $4.89 $1.19 $16.78
2019 $0.7 $0.44 $0.7
2018 $0.06 $0.06

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.